ArticleBlood cells, molecules & diseases2016
JAK2
Article in Blood cells, molecules & diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 34 citations in OpenAlex.
- Targeting Thrombopoietin/MPL Signaling to Mitigate JAK2V617F-Driven Cardiac Microvascular Disease.Arteriosclerosis, thrombosis, and vascular biology · 2026Article
- What Explains the Pattern of Fibrosis in Chronic Graft-Versus-Host Disease?Clinical transplantation · 2026Review
- Immunomodulatory role of megakaryocytes in the hematopoietic niche of myeloproliferative neoplasms.Haematologica · 2026Article
- Targeting TPO/MPL Signaling to Mitigate JAK2V617F-driven Cardiac Microvascular Disease.bioRxiv : the preprint server for biology · 2026Article
- The possible role of mutated endothelial cells in myeloproliferative neoplasms.Haematologica · 2021Review
- New Markers of Disease Progression in Myelofibrosis.Cancers · 2021Review
- JAK2V617F mutant endothelial cells promote neoplastic hematopoiesis in a mixed vascular microenvironment.Blood cells, molecules & diseases · 2021Article
- Cell competition between wild-type and JAK2V617F mutant cells in a murine model of a myeloproliferative neoplasm.Experimental hematology · 2021Article
- A Murine Model With JAK2V617F Expression in Both Hematopoietic Cells and Vascular Endothelial Cells Recapitulates the Key Features of Human Myeloproliferative Neoplasm.Frontiers in oncology · 2021Article
- Endothelial JAK2V617F mutation leads to thrombosis, vasculopathy, and cardiomyopathy in a murine model of myeloproliferative neoplasm.Journal of thrombosis and haemostasis : JTH · 2020Article
- In Vitro Modeling of Non-Solid Tumors: How Far Can Tissue Engineering Go?International journal of molecular sciences · 2020Review
- The marrow stem cell niche in normal and malignant hematopoiesis.Annals of the New York Academy of Sciences · 2020Review
- Redistribution, homing and organ-invasion of neoplastic stem cells in myeloid neoplasms.Seminars in cancer biology · 2020Review
- Addressing and proposing solutions for unmet clinical needs in the management of myeloproliferative neoplasm-associated thrombosis: A consensus-based position paper.Blood cancer journal · 2019Article
- Functional interdependence of hematopoietic stem cells and their niche in oncogene promotion of myeloproliferative neoplasms: the 159th biomedical version of "it takes two to tango".Experimental hematology · 2019Review
- JAK2V617F Megakaryocytes Promote Hematopoietic Stem/Progenitor Cell Expansion in Mice Through Thrombopoietin/MPL Signaling.Stem cells (Dayton, Ohio) · 2018Article
- The regulation of normal and neoplastic hematopoiesis is dependent on microenvironmental cells.Advances in biological regulation · 2018Review
- Article
- Modeling the human bone marrow niche in mice: From host bone marrow engraftment to bioengineering approaches.The Journal of experimental medicine · 2018Review
- The JAK2V617F-bearing vascular niche promotes clonal expansion in myeloproliferative neoplasms.Leukemia · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
The myeloproliferative neoplasms (MPNs) are characterized by hematopoietic stem/progenitor cell (HSPC) expansion and overproduction of blood cells. The acquired mutation JAK2
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.